The bill mandates the Iowa Department of Health and Human Services (HHS) to conduct a comprehensive review of anti-obesity medications as part of the medical assistance program under chapter 249A. This review will assess the effectiveness of these medications, their impact on comorbidities, potential cost savings from deferred medical procedures, and reduced medication needs related to comorbidities. Additionally, HHS is tasked with establishing recommended eligibility requirements and any other relevant criteria deemed necessary for the review.

HHS is required to compile its findings and proposed eligibility requirements into a report, which must be submitted to the General Assembly by December 1, 2025. This initiative aims to enhance the understanding and management of anti-obesity medications within the state's Medicaid program, ultimately contributing to better health outcomes and cost efficiency in healthcare delivery.